U.S. Online Retail and Ecommerce Stock News

Easterly Government Properties (DEA) has drawn attention after recent share price moves, with the stock showing an 11.4% gain over the past month and a 20.8% total return over the past year. See our latest analysis for Easterly Government Properties. The recent 11.4% 1 month share price return, alongside a 20.8% 1 year total shareholder return but weaker 3 and 5 year total shareholder returns, points to momentum building in the near term after a tougher longer run. If this kind of rebound has...

Camden Property Trust (CPT) opened 2026 with Q1 revenue of US$390.0 million, basic EPS of US$0.40 and net income of US$42.4 million, alongside Funds From Operations of US$122.9 million that many investors watch closely for a residential REIT. Over the past several quarters, revenue has moved from US$387.8 million in Q4 2024 to a range between US$393.1 million and US$399.2 million across 2025, while basic EPS has shifted between US$0.36 and US$1.44 over that same period. Taken together with a...

ResMed (RMD) has put up another solid quarter, with Q2 2026 revenue at about US$1.4b and basic EPS of US$2.69, while the trailing 12 month figures sit at US$5.4b of revenue and EPS of US$10.16. Over the past six reported quarters, revenue has moved from US$1,224.5m in Q1 2025 to US$1,422.8m in Q2 2026 and basic EPS has shifted from US$2.12 to US$2.69. This gives a clear view of the top line and per share earnings trend across the recent reporting run. With trailing 12 month earnings up 19%...

Last week saw the newest first-quarter earnings release from Omnicom Group Inc. ( NYSE:OMC ), an important milestone in...

Last week, you might have seen that Microsoft Corporation ( NASDAQ:MSFT ) released its third-quarter result to the...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

UFP Industries, Inc. ( NASDAQ:UFPI ) just released its latest first-quarter report and things are not looking great. It...

Woodward, Inc. ( NASDAQ:WWD ) investors will be delighted, with the company turning in some strong numbers with its...

While Culp, Inc. ( NASDAQ:CULP ) might not have the largest market cap around , it received a lot of attention from a...

Some Northern Trust Corporation ( NASDAQ:NTRS ) shareholders may be a little concerned to see that the Executive VP...

Investors in Automatic Data Processing, Inc. ( NASDAQ:ADP ) had a good week, as its shares rose 9.0% to close at US$214...

Seanergy Maritime Holdings Corp. ( NASDAQ:SHIP ), is not the largest company out there, but it received a lot of...

Compañía de Minas BuenaventuraA (NYSE:BVN) reported multiple operational and permitting milestones in Q1 2026, including the production ramp up at San Gabriel. The company received key stage 1 operating and water use permits for San Gabriel, while Yumpag and El Brocal secured capacity expansion approvals. Gold production, company wide revenue, and profitability all saw significant gains in the quarter, alongside these project advances. For investors watching NYSE:BVN, these updates come...

Wondering whether Travere Therapeutics at around US$44.12 is still offering value or if the easy gains are already behind it? This article unpacks what the current price really implies. The stock has shown strong share price moves, with returns of 8.9% over 7 days, 40.4% over 30 days, 11.6% year to date, 108.6% over 1 year, 162.6% over 3 years and 120.5% over 5 years. This naturally raises questions about both upside potential and risk. Recent headlines around Travere Therapeutics have...

Bristol-Myers Squibb (BMY) opened 2026 with Q1 revenue of US$11.5b, basic EPS of US$1.31 and net income of US$2.7b, setting the tone for how investors will judge its recent profitability. The company has seen quarterly revenue move from US$11.2b and basic EPS of US$1.21 in Q1 2025 to US$11.5b and US$1.31 in Q1 2026. Trailing twelve month EPS reached US$3.57, giving a clearer read on earnings power over the last year. With trailing net profit margin at 15% and recent earnings growth of 34.2%...

Eastman Chemical Q1 2026 earnings: headline numbers in focus Eastman Chemical (EMN) has opened 2026 with Q1 revenue of US$2.2b and basic EPS of US$0.94, setting the stage for how investors assess the latest move in profitability. Over recent quarters the company has seen revenue move between US$2.0b and US$2.3b, with basic EPS ranging from US$0.41 to US$2.85, while trailing twelve month EPS sits at US$3.49 on revenue of US$8.6b. With the stock at US$77.53 and trailing net margin at 4.6%...

T. Rowe Price Group (TROW) opened 2026 with Q1 revenue of US$1.9 billion and basic EPS of US$2.23, alongside trailing twelve month revenue of US$7.4 billion and EPS of US$9.34 that sit against modest 1.9% annual revenue growth and a 27.6% net profit margin over the past year. Over recent quarters, revenue has ranged from US$1.7 billion to US$1.9 billion, while quarterly EPS has moved between roughly US$1.93 and US$2.88. This provides a consistent picture of earnings power, even as the five...

Smokey Bones, the barbecue chain originally founded by Darden Restaurants, has been fully closed after a 27 year run. The shutdown ends a long standing brand legacy that traces back to Darden’s earlier expansion in American casual dining. Although Darden no longer owns Smokey Bones, the closure adds context for investors tracking NYSE:DRI and the broader barbecue and casual dining space. Darden Restaurants, trading as NYSE:DRI, is coming off a mixed share performance backdrop, with the...

If you are wondering whether Kimco Realty's current share price lines up with its underlying value, this article walks through the key numbers so you can judge that for yourself. Over recent periods the stock has seen mixed returns, with a 1.3% decline over the last 7 days, a 4.1% gain over 30 days, 16.6% year to date, 16.0% over 1 year, 43.7% over 3 years and 35.3% over 5 years. Recent coverage of Kimco Realty has focused on its role as a large retail REIT and how investors are weighing...

Neurocrine Biosciences (NasdaqGS:NBIX) reported new two‑year Phase 3 data from its CAHtalyst Pediatric and Adult trials of CRENESSITY in classic congenital adrenal hyperplasia. The peer‑reviewed results cover both children and adults and highlight durable efficacy alongside physiologic glucocorticoid dosing. Data show sustained reductions in harmful steroid exposure and clinical improvements, including better body mass index and insulin resistance in pediatric patients. These findings...

CCC Intelligent Solutions Holdings launched mobile invoice scanning in the CCC ONE platform, integrating directly into its repair management workflow. The new feature uses AI to match invoice line items to repair orders, automating parts reconciliation for repair shops. The capability is available at no additional cost to users of CCC ONE, aiming to cut manual data entry and reduce processing time. CCC Intelligent Solutions Holdings, traded as NasdaqGS:CCC, is rolling out this product...

Garmin (NYSE:GRMN) reports record Q1 2026 revenue and operating income, setting new highs for the company. Fitness segment revenue rises 42% in Q1 2026, supported by advanced wearables and recent product launches. Garmin plans around 100 product launches in 2026 across its diversified segments. The company secures multiple new EASA certifications for aviation equipment, expanding its presence in the European market. For investors tracking consumer electronics and aerospace, Garmin sits at...

Banco Latinoamericano de Comercio Exterior S. A. gained shareholder approval at its recent Annual Shareholders' Meeting to change its legal name to Bladex Inc. The rebranding will shift the company’s official identity while it continues to trade on the NYSE under ticker NYSE:BLX. The name change is expected to influence how the bank presents itself to clients, investors, and counterparties across Latin America and beyond. The rebrand to Bladex Inc. comes at a time when NYSE:BLX shares are...

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax for locally advanced pancreatic cancer and has started its U.S. commercial launch. The new therapy has seen early adoption and payer coverage in the U.S., expanding NovoCure's reach beyond its original focus in glioblastoma. Pivotal Phase 3 data from the TRIDENT trial in newly diagnosed glioblastoma are expected later this year. NovoCure focuses on tumor treating fields therapy, a medical technology designed to disrupt cancer...